1. Home
  2. PUBM vs PRAX Comparison

PUBM vs PRAX Comparison

Compare PUBM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PubMatic Inc.

PUBM

PubMatic Inc.

HOLD

Current Price

$9.18

Market Cap

406.5M

Sector

Technology

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$267.06

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUBM
PRAX
Founded
2006
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
406.5M
4.0B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
PUBM
PRAX
Price
$9.18
$267.06
Analyst Decision
Buy
Strong Buy
Analyst Count
10
14
Target Price
$18.45
$304.43
AVG Volume (30 Days)
650.3K
1.1M
Earning Date
11-10-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$288,382,000.00
$7,463,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
364.98
52 Week Low
$7.01
$26.70
52 Week High
$17.32
$278.44

Technical Indicators

Market Signals
Indicator
PUBM
PRAX
Relative Strength Index (RSI) 53.05 71.53
Support Level $8.91 $251.00
Resistance Level $9.24 $278.44
Average True Range (ATR) 0.34 17.08
MACD 0.00 6.49
Stochastic Oscillator 65.48 90.84

Price Performance

Historical Comparison
PUBM
PRAX

About PUBM PubMatic Inc.

PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Share on Social Networks: